Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1991-2-28
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0278-2677
|
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:pagination |
839-41
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2125540-Ampicillin,
pubmed-meshheading:2125540-Cephalosporins,
pubmed-meshheading:2125540-Cost-Benefit Analysis,
pubmed-meshheading:2125540-Drug Therapy, Combination,
pubmed-meshheading:2125540-Female,
pubmed-meshheading:2125540-Humans,
pubmed-meshheading:2125540-Pelvic Inflammatory Disease,
pubmed-meshheading:2125540-Sulbactam
|
pubmed:year |
1990
|
pubmed:articleTitle |
Antimicrobial treatment of pelvic inflammatory disease.
|
pubmed:publicationType |
Letter,
Comment
|